Viral proteases as therapeutic targets

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F22%3A00565334" target="_blank" >RIV/61388963:_____/22:00565334 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11310/22:10458302

Výsledek na webu

<a href="https://doi.org/10.1016/j.mam.2022.101159" target="_blank" >https://doi.org/10.1016/j.mam.2022.101159</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.mam.2022.101159" target="_blank" >10.1016/j.mam.2022.101159</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Viral proteases as therapeutic targets

Popis výsledku v původním jazyce

Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and herpesviruses―code for a protease, which is indispensable for viral maturation and pathogenesis. Viral protease inhibitors have become an important class of antiviral drugs. Development of the first-in-class viral protease inhibitor saquinavir, which targets HIV protease, started a new era in the treatment of chronic viral diseases. Combining several drugs that target different steps of the viral life cycle enables use of lower doses of individual drugs (and thereby reduction of potential side effects, which frequently occur during long term therapy) and reduces drug-resistance development. Currently, several HIV and HCV protease inhibitors are routinely used in clinical practice. In addition, a drug including an inhibitor of SARS-CoV-2 main protease, nirmatrelvir (co-administered with a pharmacokinetic booster ritonavir as Paxlovid®), was recently authorized for emergency use. This review summarizes the basic features of the proteases of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and SARS-CoV-2 and discusses the properties of their inhibitors in clinical use, as well as development of compounds in the pipeline.

Název v anglickém jazyce

Viral proteases as therapeutic targets

Popis výsledku anglicky

Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and herpesviruses―code for a protease, which is indispensable for viral maturation and pathogenesis. Viral protease inhibitors have become an important class of antiviral drugs. Development of the first-in-class viral protease inhibitor saquinavir, which targets HIV protease, started a new era in the treatment of chronic viral diseases. Combining several drugs that target different steps of the viral life cycle enables use of lower doses of individual drugs (and thereby reduction of potential side effects, which frequently occur during long term therapy) and reduces drug-resistance development. Currently, several HIV and HCV protease inhibitors are routinely used in clinical practice. In addition, a drug including an inhibitor of SARS-CoV-2 main protease, nirmatrelvir (co-administered with a pharmacokinetic booster ritonavir as Paxlovid®), was recently authorized for emergency use. This review summarizes the basic features of the proteases of human immunodeficiency virus (HIV), hepatitis C virus (HCV), and SARS-CoV-2 and discusses the properties of their inhibitors in clinical use, as well as development of compounds in the pipeline.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10607 - Virology

Projekt

<a href="/cs/project/LX22NPO5103" target="_blank" >LX22NPO5103: Národní institut virologie a bakteriologie</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Aspects of Medicine

ISSN

0098-2997

e-ISSN

1872-9452

Svazek periodika

88

Číslo periodika v rámci svazku

December

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

24

Strana od-do

101159

Kód UT WoS článku

000926142300002

EID výsledku v databázi Scopus

2-s2.0-85142806051